{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:08:31Z","timestamp":1793210911508,"version":"4.5.0"},"reference-count":205,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.survophthal.2012.08.003","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T03:36:38Z","timestamp":1371180998000},"page":"291-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"title":["Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review"],"prefix":"10.1016","volume":"58","author":[{"given":"Weerawat","family":"Kiddee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham E.","family":"Trope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Beltran-Agullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hermina","family":"Strungaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasrajbir","family":"Baath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.","family":"Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2012.08.003_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajo.2004.05.031","article-title":"Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide","volume":"138","author":"Agrawal","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1874364100802010119","article-title":"Intraocular pressure following intravitreal injection of triamcinolone acetonide","volume":"2","author":"Ansari","year":"2008","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.survophthal.2012.08.003_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archopht.1963.00960050484010","article-title":"Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye","volume":"70","author":"Armaly","year":"1963","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archopht.1963.00960050494011","article-title":"Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye","volume":"70","author":"Armaly","year":"1963","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib5","first-page":"187","article-title":"Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response","volume":"4","author":"Armaly","year":"1965","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00417-006-0514-0","article-title":"Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behcet\u2019s disease","volume":"245","author":"Atmaca","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1600-0420.2006.00700.x","article-title":"Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial","volume":"84","author":"Audren","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2012.08.003_bib8","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1167\/iovs.03-1110","article-title":"Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema","volume":"45","author":"Audren","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1442-9071.2006.01103.x","article-title":"Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema","volume":"34","author":"Avci","year":"2006","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00417-005-0069-5","article-title":"Intravitreal triamcinolone injection for chronic diabetic macular oedema with severe hard exudates","volume":"244","author":"Avci","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ajo.2005.05.021","article-title":"Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema","volume":"140","author":"Avitabile","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1089\/jop.2006.125","article-title":"Safety profile of intravitreal triamcinolone acetonide","volume":"23","author":"Baath","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2012.08.003_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3928\/1542-8877-20030901-08","article-title":"The effect of intravitreal triamcinolone acetonide on intraocular pressure","volume":"34","author":"Bakri","year":"2003","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.survophthal.2012.08.003_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.eye.6702938","article-title":"Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab","volume":"23","author":"Bakri","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0960-0760(96)00167-7","article-title":"Inhibition of mineralocorticoid activity by the beta-isoform of the human glucocorticoid receptor","volume":"60","author":"Bamberger","year":"1997","journal-title":"J Steroid Biochem Mol Biol."},{"key":"10.1016\/j.survophthal.2012.08.003_bib16","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.3129\/i09-084","article-title":"Selective laser trabeculoplasty for the treatment of intraocular pressure elevation after intravitreal triamcinolone injection","volume":"44","author":"Baser","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib17","first-page":"269","article-title":"Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors","volume":"2","author":"Bashshur","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10792-007-9072-7","article-title":"Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema","volume":"27","author":"Batioglu","year":"2007","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archophthalmol.2008.610","article-title":"Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema","volume":"127","author":"Beck","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","article-title":"Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib21","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ophtha.2005.10.061","article-title":"Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide","volume":"113","author":"Benz","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib22","first-page":"58","article-title":"The response pattern of intravitreal triamcinolone injection for non-AMD macular edema","volume":"92","author":"Bhurayanontachai","year":"2009","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.survophthal.2012.08.003_bib23","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ophtha.2011.02.042","article-title":"Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis","volume":"118","author":"Bollinger","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ICU.0b013e32831d7f3a","article-title":"Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant","volume":"20","author":"Bollinger","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib25","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.addr.2006.07.026","article-title":"Intraocular implants for extended drug delivery: therapeutic applications","volume":"58","author":"Bourges","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.survophthal.2012.08.003_bib26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","article-title":"Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients","volume":"31","author":"Boyer","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1167\/iovs.08-2625","article-title":"Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection","volume":"50","author":"Breusegem","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/IAE.0b013e318154b9d1","article-title":"Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation","volume":"28","author":"Cakir","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib30","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib31","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ophtha.2009.11.024","article-title":"Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.eye.6701585","article-title":"Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study","volume":"19","author":"Chan","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3928\/15428877-20091230-05","article-title":"Intravitreal dexamethasone for diabetic macular edema: a pilot study","volume":"41","author":"Chan","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.survophthal.2012.08.003_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/112067210701700514","article-title":"Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection","volume":"17","author":"Chang","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1607-551X(08)70100-1","article-title":"Elevation of intraocular pressure after intravitreal injection of triamcinolone acetonide in Taiwanese patients","volume":"24","author":"Chang","year":"2008","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib37","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1167\/iovs.10-6387","article-title":"Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib38","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.ophtha.2007.02.013","article-title":"Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial","volume":"114","author":"Chaudhary","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/bjo.2003.033589","article-title":"Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema","volume":"88","author":"Chen","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib40","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2005.12.011","article-title":"Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion","volume":"141","author":"Chen","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1755-3768.2008.01172.x","article-title":"Argon laser trabeculoplasty for late glaucoma after intravitreal triamcinolone","volume":"87","author":"Chen","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib42","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ophtha.2009.01.039","article-title":"Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection","volume":"116","author":"Cheng","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ajo.2008.05.035","article-title":"Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis","volume":"146","author":"Chieh","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib44","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/00006982-200510000-00002","article-title":"Intravitreal triamcinolone acetonide for diabetic macular edema","volume":"25","author":"Chieh","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib45","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006982-200507000-00002","article-title":"Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes","volume":"25","author":"Chin","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3341\/kjo.2006.20.4.205","article-title":"Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema","volume":"20","author":"Choi","year":"2006","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib47","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/jps.21987","article-title":"A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases","volume":"99","author":"Choonara","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/jop.2010.0039","article-title":"Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion","volume":"26","author":"Chuang","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2012.08.003_bib49","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3349\/ymj.2008.49.6.955","article-title":"Comparison of combination posterior sub-tenon triamcinolone and modified grid laser treatment with intravitreal triamcinolone treatment in patients with diffuse diabetic macular edema","volume":"49","author":"Chung","year":"2008","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.survophthal.2012.08.003_bib50","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/bjo.2004.041707","article-title":"Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study","volume":"88","author":"Ciardella","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.icu.0000120711.35941.76","article-title":"Corticosteroids in posterior segment disease: An update on new delivery systems and new indications","volume":"15","author":"Ciulla","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib52","first-page":"281","article-title":"Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells","volume":"35","author":"Clark","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.exer.2008.10.004","article-title":"The role of steroids in outflow resistance","volume":"88","author":"Clark","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2012.08.003_bib54","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jcrs.2007.04.029","article-title":"Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract","volume":"33","author":"Dada","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.survophthal.2012.08.003_bib55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00006982-200003000-00004","article-title":"Intravitreal triamcinolone acetonide in exudative age-related macular degeneration","volume":"20","author":"Danis","year":"2000","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drudis.2007.11.002","article-title":"Current and future ophthalmic drug delivery systems. A shift to the posterior segment","volume":"13","author":"Del Amo","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.survophthal.2012.08.003_bib57","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","article-title":"A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib58","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Diabetic Retinopathy Clinical Research Network","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib59","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/IAE.0b013e3181f4420d","article-title":"Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion","volume":"31","author":"Ding","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib60","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib61","first-page":"1075","article-title":"Corticosteroid glaucoma","volume":"9","author":"Fran\u00e7ois","year":"1977","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib62","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1001\/archophthalmol.2010.297","article-title":"Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections","volume":"128","author":"Frenkel","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib63","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.ophtha.2007.05.037","article-title":"Adverse events after intravitreal triamcinolone in patients with and without uveitis","volume":"114","author":"Galor","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib64","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0420.2005.00605.x","article-title":"Macular oedema in central retinal vein occlusion treated with intravitreal triamcinolone","volume":"84","author":"Gelston","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2012.08.003_bib65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ophtha.2004.07.017","article-title":"Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract","volume":"112","author":"Gillies","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib66","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ophtha.2010.09.029","article-title":"Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial","volume":"118","author":"Gillies","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib67","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/archopht.122.3.336","article-title":"Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial","volume":"122","author":"Gillies","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib68","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archopht.121.5.667","article-title":"A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results","volume":"121","author":"Gillies","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib69","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial","volume":"113","author":"Gillies","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib70","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/01.iae.0000231543.45699.e1","article-title":"Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion","volume":"26","author":"Goff","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib71","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/archopht.125.11.ecs70063","article-title":"Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants","volume":"125","author":"Goldstein","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archopht.1974.01010010155016","article-title":"Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis","volume":"92","author":"Graham","year":"1974","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib73","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/01.iae.0000237111.82357.30","article-title":"One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion","volume":"26","author":"Gregori","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib74","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib75","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/IAE.0b013e318188c814","article-title":"Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema","volume":"29","author":"Haller","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00004397-200004000-00015","article-title":"New and emerging treatments for patients with uveitis","volume":"40","author":"Haupert","year":"2000","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.survophthal.2012.08.003_bib79","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/IAE.0b013e318165767e","article-title":"Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg","volume":"28","author":"Hauser","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib80","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.survophthal.2012.08.003_bib81","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10384-009-0692-5","article-title":"Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes","volume":"53","author":"Hirano","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib82","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/112067210801800318","article-title":"Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis","volume":"18","author":"Hogewind","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib83","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3129\/i10-050","article-title":"A trial of topical prednisolone acetate before intravitreal triamcinolone acetonide decreases intraocular pressure spikes","volume":"45","author":"Hollands","year":"2010","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib84","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3129\/i07-172","article-title":"Short-term intraocular pressure changes after intravitreal injection of bevacizumab","volume":"42","author":"Hollands","year":"2007","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib85","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3760\/cma.j.issn.0366-6999.2009.22.004","article-title":"Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study","volume":"122","author":"Hou","year":"2009","journal-title":"Chin Med J"},{"key":"10.1016\/j.survophthal.2012.08.003_bib86","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/IJG.0b013e31814b9948","article-title":"A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection","volume":"17","author":"Im","year":"2008","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2012.08.003_bib87","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ajo.2007.12.010","article-title":"Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study","volume":"145","author":"Inatani","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib88","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib89","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000090577","article-title":"Intravitreal triamcinolone acetonide for exudative age-related macular degeneration among Japanese patients","volume":"220","author":"Ito","year":"2006","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2012.08.003_bib90","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib91","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ophtha.2005.03.013","article-title":"Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis","volume":"112","author":"Jaffe","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib92","first-page":"3569","article-title":"Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device","volume":"41","author":"Jaffe","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3341\/kjo.2006.20.2.99","article-title":"Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis","volume":"20","author":"Jea","year":"2006","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib94","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archopht.1997.01100150377011","article-title":"Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids","volume":"115","author":"Johnson","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib95","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archopht.122.2.218","article-title":"Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration","volume":"122","author":"Jonas","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib96","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/112067210501500615","article-title":"Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion","volume":"15","author":"Jonas","year":"2005","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib97","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ophtha.2004.10.042","article-title":"Intraocular pressure elevation after intravitreal triamcinolone acetonide injection","volume":"112","author":"Jonas","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib98","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bjo.84.9.1064","article-title":"Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy","volume":"84","author":"Jonas","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib99","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9394(00)00882-5","article-title":"Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy","volume":"131","author":"Jonas","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ajo.2003.08.012","article-title":"Intraocular availability of triamcinolone acetonide after intravitreal injection","volume":"137","author":"Jonas","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib101","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bjo.87.1.24","article-title":"Intraocular pressure after intravitreal injection of triamcinolone acetonide","volume":"87","author":"Jonas","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib102","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/bjo.87.4.462","article-title":"Intravitreal triamcinolone acetonide for exudative age related macular degeneration","volume":"87","author":"Jonas","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archopht.121.1.57","article-title":"Intravitreal injection of triamcinolone for diffuse diabetic macular edema","volume":"121","author":"Jonas","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib104","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.eye.6702734","article-title":"Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases","volume":"22","author":"Jonas","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/112067210601600411","article-title":"Follow-up after intravitreal triamcinolone acetonide for diabetic macular edema","volume":"16","author":"Jonas","year":"2006","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib106","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ophtha.2006.01.002","article-title":"Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema","volume":"113","author":"Jonas","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib107","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.eye.6702222","article-title":"Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration","volume":"21","author":"Jonas","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib108","first-page":"163","article-title":"Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature","volume":"17","author":"Jones","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib109","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ophtha.2008.01.019","article-title":"Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye","volume":"115","author":"Kamppeter","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib110","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","article-title":"Iluvien: a new sustained delivery technology for posterior eye disease","volume":"5","author":"Kane","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.survophthal.2012.08.003_bib111","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ajo.2007.07.044","article-title":"Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema","volume":"144","author":"Kang","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib112","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/sj.eye.6701512","article-title":"Intravitreal triamcinolone as a primary therapy in diabetic macular oedema","volume":"19","author":"Karacorlu","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib113","first-page":"758","article-title":"Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion","volume":"137","author":"Kaushik","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib114","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1755-3768.2009.01656.x","article-title":"Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection?","volume":"89","author":"Kerimoglu","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib116","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.eye.6701895","article-title":"Corticosteroid-induced glaucoma: a review of the literature","volume":"20","author":"Kersey","year":"2006","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib117","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00006982-200605000-00005","article-title":"Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration","volume":"26","author":"Kim","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib118","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents","volume":"146","author":"Kim","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib119","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/IAE.0b013e318163194c","article-title":"ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema","volume":"28","author":"Kim","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3341\/kjo.2009.23.4.259","article-title":"Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion","volume":"23","author":"Kim","year":"2009","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib121","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archopht.1981.03930010819005","article-title":"The prognosis of corticosteroid-responsive individuals","volume":"99","author":"Kitazawa","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib122","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/OPTH.S2359","article-title":"Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone","volume":"2","author":"Kocabora","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib123","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10384-007-0513-7","article-title":"Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema","volume":"52","author":"Kogure","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.eye.6702416","article-title":"Ocular morbidity associated with intravitreal triamcinolone acetonide","volume":"21","author":"Konstantopoulos","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib125","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/bjo.2005.088278","article-title":"Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye","volume":"90","author":"Kosobucki","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib126","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1600-0420.2007.00939.x","article-title":"Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model","volume":"85","author":"Kotliar","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2012.08.003_bib127","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079907X187946","article-title":"The effect of intravitreal triamcinolone on intraocular pressure","volume":"23","author":"Kramar","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.survophthal.2012.08.003_bib128","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/archopht.125.9.1284","article-title":"Viscocanalostomy for refractory glaucoma secondary to intravitreal triamcinolone acetonide injection","volume":"125","author":"Krishnan","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00061198-200604000-00007","article-title":"Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide","volume":"15","author":"Kubota","year":"2006","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2012.08.003_bib130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib131","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","article-title":"Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection","volume":"110","author":"Kwak","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bjo.2006.102848","article-title":"A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema","volume":"91","author":"Lam","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib133","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/sj.eye.6701686","article-title":"Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study","volume":"19","author":"Lam","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib134","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1442-9071.2004.00903.x","article-title":"Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study","volume":"32","author":"Lam","year":"2004","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib135","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ophtha.2006.08.044","article-title":"Evaluation of intravitreal kenalog toxicity in humans","volume":"114","author":"Lang","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib136","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ajo.2008.05.034","article-title":"Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population","volume":"146","author":"Lau","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib137","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archophthalmol.2011.214","article-title":"Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the diabetic retinopathy clinical research network","volume":"129","author":"Lauer","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib138","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0002-9394(88)90595-8","article-title":"Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma","volume":"106","author":"Lewis","year":"1988","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib139","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12325-011-0019-z","article-title":"The dexamethasone drug delivery system: indications and evidence","volume":"28","author":"London","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2012.08.003_bib141","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib142","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.ophtha.2009.04.032","article-title":"Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial","volume":"116","author":"Maberley","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib143","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ajo.2006.03.003","article-title":"Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization","volume":"142","author":"Marticorena","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib144","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema","volume":"109","author":"Martidis","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib145","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00006982-200412000-00009","article-title":"Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes","volume":"24","author":"Mason","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib146","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2003.05.037","article-title":"Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial","volume":"111","author":"Massin","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib147","first-page":"1902","article-title":"Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ","volume":"38","author":"Matsumoto","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib148","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/IAE.0b013e3181b4f125","article-title":"Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema","volume":"30","author":"Mirshahi","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib149","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ajo.2004.03.025","article-title":"Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema","volume":"138","author":"Moshfeghi","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10792-006-0005-7","article-title":"Effects of intravitreal triamcinolone injection on macular edema and visual prognosis in central retinal vein occlusion","volume":"26","author":"Ozdek","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib151","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0008-4182(05)80119-X","article-title":"Complications of intravitreal injection of triamcinolone acetonide","volume":"40","author":"Ozkiris","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib152","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.eye.6701803","article-title":"Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion","volume":"20","author":"Ozkiris","year":"2006","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib153","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/112067210401400615","article-title":"Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema","volume":"14","author":"Ozkiris","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib154","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3341\/kjo.2005.19.2.122","article-title":"Intraocular pressure elevation after intravitreal triamcinolone acetonide injection","volume":"19","author":"Park","year":"2005","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib155","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ophtha.2009.11.027","article-title":"Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis","volume":"117","author":"Pavesio","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib156","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","article-title":"Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial","volume":"118","author":"Pearson","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib157","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.opx.0000225106.52653.72","article-title":"Selective laser trabeculoplasty for intraocular pressure elevation after intravitreal triamcinolone acetonide injection","volume":"83","author":"Pizzimenti","year":"2006","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib158","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000310780","article-title":"Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product","volume":"211","author":"Polansky","year":"1997","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2012.08.003_bib159","first-page":"640","article-title":"Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head","volume":"16","author":"Quigley","year":"1977","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2008.03.025","article-title":"Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results","volume":"146","author":"Ramchandran","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib161","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-006-0348-9","article-title":"Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial","volume":"244","author":"Ramezani","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib162","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bjo.2006.090340","article-title":"Intraocular pressure alterations following intravitreal triamcinolone acetonide","volume":"90","author":"Rhee","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib163","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/112067210601600516","article-title":"Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment","volume":"16","author":"Ricci","year":"2006","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib164","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/IAE.0b013e3181593e38","article-title":"Short-term complications of intravitreal injection of triamcinolone acetonide","volume":"28","author":"Roth","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib165","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ophtha.2008.10.002","article-title":"Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection","volume":"116","author":"Roth","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib166","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/IJG.0b013e318031676c","article-title":"The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure","volume":"17","author":"Rubin","year":"2008","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2012.08.003_bib167","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/IJG.0b013e31816b3037","article-title":"Secondary elevated IOP and cataracts after high-dose intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization","volume":"18","author":"Ruiz-Moreno","year":"2009","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2012.08.003_bib168","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archopht.123.1.129-b","article-title":"Anterior chamber transit of triamcinolone after intravitreal injection","volume":"123","author":"Ruiz-Moreno","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib169","first-page":"251","article-title":"The cytoskeleton of the cultured human trabecular cell. Characterization and drug responses","volume":"29","author":"Ryder","year":"1988","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib170","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0002-9394(82)90130-1","article-title":"The clearance of intravitreal triamcinolone acetonide","volume":"93","author":"Schindler","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib171","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/archopht.1985.01050100143037","article-title":"Clearance of triamcinolone from vitreous","volume":"103","author":"Scholes","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib172","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/archopht.125.6.759","article-title":"Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone","volume":"125","author":"Scorolli","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib173","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00003226-200405000-00016","article-title":"Pseudohypopyon following intravitreal triamcinolone acetonide injection","volume":"23","author":"Sharma","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.08.003_bib174","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajo.2007.04.021","article-title":"Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone","volume":"144","author":"Shukla","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1442-9071.2009.02185.x","article-title":"Pseudohypopyon following intravitreal triamcinolone acetonide injection in a phakic eye","volume":"38","author":"Simon","year":"2010","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib176","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajo.2004.03.001","article-title":"Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection","volume":"138","author":"Singh","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib177","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1600-0420.2006.00698.x","article-title":"Intravitreal steroids in the management of macular oedema","volume":"84","author":"Sivaprasad","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2012.08.003_bib178","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ajo.2004.06.067","article-title":"Intravitreal triamcinolone acetonide and intraocular pressure","volume":"138","author":"Smithen","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib179","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/exer.1993.1148","article-title":"Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants","volume":"57","author":"Snyder","year":"1993","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2012.08.003_bib180","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1126\/science.275.5300.668","article-title":"Identification of a gene that causes primary open angle glaucoma","volume":"275","author":"Stone","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.survophthal.2012.08.003_bib181","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2004.05.025","article-title":"Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial","volume":"111","author":"Sutter","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.08.003_bib182","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bjo.2007.126227","article-title":"Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections","volume":"92","author":"Tammewar","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib183","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0002-9394(14)75196-7","article-title":"Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide","volume":"90","author":"Tano","year":"1980","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib184","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/eye.2009.220","article-title":"Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion","volume":"24","author":"Tao","year":"2010","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.08.003_bib185","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00417-008-0800-0","article-title":"Immunohistochemical evaluation of the extracellular matrix in trabecular meshwork in steroid-induced glaucoma","volume":"246","author":"Tawara","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib186","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.exer.2008.11.025","article-title":"Structural changes of the trabecular meshwork in different kinds of glaucoma","volume":"88","author":"Tektas","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2012.08.003_bib187","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.survophthal.2012.08.003_bib188","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004397-200004000-00014","article-title":"Appraisal and management of ocular hypotony and glaucoma associated with uveitis","volume":"40","author":"Tran","year":"2000","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.survophthal.2012.08.003_bib189","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2007.0015","article-title":"Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease","volume":"23","author":"Tuncer","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2012.08.003_bib190","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1152\/ajpcell.1999.277.2.C330","article-title":"Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions","volume":"277","author":"Underwood","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib191","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IAE.0b013e31816079e8","article-title":"Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors","volume":"28","author":"Vasconcelos-Santos","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.08.003_bib192","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archopht.124.1.133","article-title":"Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone","volume":"124","author":"Viola","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib193","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1442-9071.2007.01492.x","article-title":"Late intraocular pressure rise following intravitreal triamcinolone injection","volume":"35","author":"Williams","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib194","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/02713689309020383","article-title":"Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells","volume":"12","author":"Wilson","year":"1993","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2012.08.003_bib195","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1440-1606.1999.00238.x","article-title":"Intravitreal triamcinolone and elevated intraocular pressure","volume":"27","author":"Wingate","year":"1999","journal-title":"Aust NZ J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib196","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1350-9462(98)00035-4","article-title":"Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma","volume":"18","author":"Wordinger","year":"1999","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2012.08.003_bib197","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3129\/i07-186","article-title":"Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection","volume":"43","author":"Yamamoto","year":"2008","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib198","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/IJG.0b013e31802d6e16","article-title":"Intraocular pressure after intravitreal injection of triamcinolone acetonide following vitrectomy for macular edema","volume":"16","author":"Yamashita","year":"2007","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2012.08.003_bib199","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s10384-003-0053-8","article-title":"Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone","volume":"48","author":"Yeung","year":"2004","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.08.003_bib200","article-title":"Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma","author":"Yuen","year":"2011","journal-title":"J Glaucoma [Internet]"},{"key":"10.1016\/j.survophthal.2012.08.003_bib201","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1167\/iovs.05-0571","article-title":"Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta","volume":"46","author":"Zhang","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.08.003_bib202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.exer.2006.09.022","article-title":"Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta","volume":"84","author":"Zhang","year":"2007","journal-title":"Exp Eye Res"},{"key":"#cr-split#-10.1016\/j.survophthal.2012.08.003_bib204.1","unstructured":"Alimera Sciences receives complete response letter from FDA for ILUVIEN [Internet]. 2011 [updated 2011 Nov 11"},{"key":"#cr-split#-10.1016\/j.survophthal.2012.08.003_bib204.2","unstructured":"cited 2011 Dec 9]. Available from: http:\/\/investor.alimerasciences.com\/releasedetail.cfm?ReleaseID=623128."},{"key":"10.1016\/j.survophthal.2012.08.003_bib205","unstructured":"The Royal College of Ophthalmologists of the United Kingdom. Guidelines for the management of open angle glaucoma and ocular hypertension [Internet]. 2004 [cited 2011 Dec 9]. Available from: http:\/\/www.rcophth.ac.uk\/page.asp?section=451&sectionTitle=Clinical+Guidelines."}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962571200183X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962571200183X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:38:25Z","timestamp":1758541105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003962571200183X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":205,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S003962571200183X"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2012.08.003","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2012.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}